Cargando…

Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients

Alpha1-chimaerin is a GTPase-activating protein (GAP) for Rac1, a member of the Rho small GTPase family, whose action leads to the inactivation of Rac1. Rac1 activity is upregulated in Alzheimer's disease, but little is known about the role of α1-chimaerin. In this study, we investigated the ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Tomoko, Konishi, Yoshihiro, Shimohama, Shun, Beach, Thomas G., Akatsu, Hiroyasu, Tooyama, Ikuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382517/
https://www.ncbi.nlm.nih.gov/pubmed/25676811
http://dx.doi.org/10.1016/j.neulet.2015.02.013
_version_ 1782364595027968000
author Kato, Tomoko
Konishi, Yoshihiro
Shimohama, Shun
Beach, Thomas G.
Akatsu, Hiroyasu
Tooyama, Ikuo
author_facet Kato, Tomoko
Konishi, Yoshihiro
Shimohama, Shun
Beach, Thomas G.
Akatsu, Hiroyasu
Tooyama, Ikuo
author_sort Kato, Tomoko
collection PubMed
description Alpha1-chimaerin is a GTPase-activating protein (GAP) for Rac1, a member of the Rho small GTPase family, whose action leads to the inactivation of Rac1. Rac1 activity is upregulated in Alzheimer's disease, but little is known about the role of α1-chimaerin. In this study, we investigated the expression and localization of α1-chimaerin mRNA in postmortem human brains from patients with Alzheimer's disease and control subjects. In situ hybridization studies demonstrated that α1-chimaerin was expressed by neurons in the neo-cortex of the temporal lobe and the hippocampus of both controls and Alzheimer's disease cases, with the signal intensity dramatically decreased in patients with Alzheimer's disease. Real-time PCR analysis confirmed a significant reduction of α1-chimaerin mRNA expression in the temporal cortex of Alzheimer's disease cases. In contrast, α2-chimaerin mRNA levels showed no significant difference between the groups. The present study showed reduced α1-chimaerin expression in the brain of Alzheimer's disease cases, suggesting a role in the upregulation of Rac1 activity during the disease process.
format Online
Article
Text
id pubmed-4382517
institution National Center for Biotechnology Information
language English
publishDate 2015
record_format MEDLINE/PubMed
spelling pubmed-43825172016-03-30 Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients Kato, Tomoko Konishi, Yoshihiro Shimohama, Shun Beach, Thomas G. Akatsu, Hiroyasu Tooyama, Ikuo Neurosci Lett Article Alpha1-chimaerin is a GTPase-activating protein (GAP) for Rac1, a member of the Rho small GTPase family, whose action leads to the inactivation of Rac1. Rac1 activity is upregulated in Alzheimer's disease, but little is known about the role of α1-chimaerin. In this study, we investigated the expression and localization of α1-chimaerin mRNA in postmortem human brains from patients with Alzheimer's disease and control subjects. In situ hybridization studies demonstrated that α1-chimaerin was expressed by neurons in the neo-cortex of the temporal lobe and the hippocampus of both controls and Alzheimer's disease cases, with the signal intensity dramatically decreased in patients with Alzheimer's disease. Real-time PCR analysis confirmed a significant reduction of α1-chimaerin mRNA expression in the temporal cortex of Alzheimer's disease cases. In contrast, α2-chimaerin mRNA levels showed no significant difference between the groups. The present study showed reduced α1-chimaerin expression in the brain of Alzheimer's disease cases, suggesting a role in the upregulation of Rac1 activity during the disease process. 2015-02-09 2015-03-30 /pmc/articles/PMC4382517/ /pubmed/25676811 http://dx.doi.org/10.1016/j.neulet.2015.02.013 Text en © 2015 Published by Elsevier Ireland Ltd. http://creativecommons.org/licenses/by/4.0/ This manuscript version is made available under the CC BY-NC-ND 4.0 license.
spellingShingle Article
Kato, Tomoko
Konishi, Yoshihiro
Shimohama, Shun
Beach, Thomas G.
Akatsu, Hiroyasu
Tooyama, Ikuo
Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients
title Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients
title_full Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients
title_fullStr Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients
title_full_unstemmed Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients
title_short Alpha1-chimaerin, a Rac1 GTPase-activating protein, is expressed at reduced mRNA levels in the brain of Alzheimer's disease patients
title_sort alpha1-chimaerin, a rac1 gtpase-activating protein, is expressed at reduced mrna levels in the brain of alzheimer's disease patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382517/
https://www.ncbi.nlm.nih.gov/pubmed/25676811
http://dx.doi.org/10.1016/j.neulet.2015.02.013
work_keys_str_mv AT katotomoko alpha1chimaerinarac1gtpaseactivatingproteinisexpressedatreducedmrnalevelsinthebrainofalzheimersdiseasepatients
AT konishiyoshihiro alpha1chimaerinarac1gtpaseactivatingproteinisexpressedatreducedmrnalevelsinthebrainofalzheimersdiseasepatients
AT shimohamashun alpha1chimaerinarac1gtpaseactivatingproteinisexpressedatreducedmrnalevelsinthebrainofalzheimersdiseasepatients
AT beachthomasg alpha1chimaerinarac1gtpaseactivatingproteinisexpressedatreducedmrnalevelsinthebrainofalzheimersdiseasepatients
AT akatsuhiroyasu alpha1chimaerinarac1gtpaseactivatingproteinisexpressedatreducedmrnalevelsinthebrainofalzheimersdiseasepatients
AT tooyamaikuo alpha1chimaerinarac1gtpaseactivatingproteinisexpressedatreducedmrnalevelsinthebrainofalzheimersdiseasepatients